Randomized factorial trial of esomeprazole and aspirin in Barrett’s oesophagus: the Aspirin and Esomeprazole Chemoprevention in Barrett’s metaplasia Trial (AspECT)Tools Jankowski, Janusz A.Z. and de Caestecker, John and Love, Sharon B. and Reilly, Gavin and Watson, Peter and Sanders, Scott and Ang, Yeng and Morris, Danielle and Bhandari, Pradeep and Attwood, Stephen and Ragunath, Krish and Rameh, Bashir and Fullarton, Grant and Tucker, Art and Penman, Ian and Rodgers, Colin and Neale, James and Brooks, Claire and Wise, Adelyn and Jones, Stephen and Church, Nicholas and Gibbons, Michael and Johnston, David and Vaidya, Kishor and Anderson, Mark and Balata, Sherzad and Davies, Gareth and Dickey, William and Goddard, Andrew and Edwards, Cathryn and Gore, Stephen and Haigh, Chris and Harding, Timothy and Isaacs, Peter and Jackson, Lucina and Lee, Thomas and Lim, Peik Loon and Macdonald, Christopher and Mairs, Philip and McLoughlin, James and Monk, David and Murdock, Andrew and Murray, Iain and Preston, Sean and Pugh, Stirling and Smart, Howard and Soliman, Ashraf and Todd, John and Turner, Graham and Worthington, Joy and Harrison, Rebecca and Barr, Hugh and Moayyedi, Paul (2018) Randomized factorial trial of esomeprazole and aspirin in Barrett’s oesophagus: the Aspirin and Esomeprazole Chemoprevention in Barrett’s metaplasia Trial (AspECT). Lancet Gastroenterology and Hepatology . ISSN 2468-1253 (In Press) Full text not available from this repository.AbstractBackground: Oesophageal adenocarcinoma (OA) is the sixth commonest cause of cancer death worldwide and Barrett’s oesophagus (BO) is the most significant risk factor. We evaluated the efficacy of high-dose esomeprazole proton pump inhibitor acid suppression (PPI) and aspirin in improving outcome for BO patients in the largest such randomized controlled trial.
Actions (Archive Staff Only)
|